# US 11,439,655 B2 · Compounds for use in wound healing and angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,655 B2
- Document ID: US11439655B2
- Status: Granted
- Kind: B2
- Application number: 16/122,087
- Filed: 2018-09-05
- Published: 2019-03-07
- Granted: 2022-09-13
- Earliest claimed: 2017-09-06
- Assignees: University of South Carolina
- Applicants: University of South Carolina
- Inventors: Ehsan Jabbarzadeh; Sara Eslambolchi Moghadam
- Web page: https://patentgrep.com/patent/US11439655B2

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61L 15/44: Medicaments
- A61L 17/005: {containing a biologically active substance, e.g. a medicament or a biocide}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/60: Materials for use in artificial skin
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61L 2300/216: with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of at least one of a flavonoid and a chlorogenic acid that are natural extracts of Parrotia persica, or their derivatives, analogues, or homologs. Compounds based upon these natural extracts have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.

## Claims

### Claim 1

A method for treatment of a wound, the method comprising contacting the wound with a composition, the composition comprising a total extract of Parrotia persica.

### Claim 2 (depends on 1)

The method of claim 1, wherein the wound comprises an acute wound, a chronic wound, or a burn.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is applied during one or more additional wound phases.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is carried by a pharmaceutical appliance.

### Claim 5 (depends on 4)

The method of claim 4, the pharmaceutical appliance comprising a suture, a stable, gauze, a bandage, a solid wound dressing, or an artificial skin.

### Claim 6 (depends on 1)

The method of claim 1, the composition being in the form of a gel, a cream, or an ointment.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is contained within a capsule.

### Claim 8 (depends on 1)

The method of claim 1, the composition further comprising one or more of quinic acid, 1-O-caffeoylquinic acid, 4-O-caffeoylqunic acid, 5-O-caffeoylquinic acid, 1,5-O-dicaffeoylquinic acid, 1,3-O-dicaffeoylquinic acid, 3,4-O-dicaffeoylquinic acid, 3,5-O-dicaffeoylquinic acid, 4,5-O-dicaffeoylquinic acid, and 3,4,5-O-tetracaffeoylquinic acid, 3,4,5-O-tricaffeoylquinic acid.

### Claim 9 (depends on 1)

The method of claim 1, the composition further comprising one or more of myricetin, myricetin-3-O-glucoside, quercetin, quercetin-3-O-glucoside, quercetin-3-O-rhamnoside, kaempferol, kaempferol-3-O-rhamnoside, kaempferol-3-O-glucoside, and luteolin-7-O-glucoside.

### Claim 10 (depends on 1)

The method of claim 1, the total extract of Parrotia persica comprising myricetin-3-O-rhamnoside and 3-O-caffeoylquinic acid.

### Claim 11 (depends on 10)

The method of claim 10, the composition comprising the myricetin-3-O-rhamnoside in an amount of from about 0.00001% to about 5% by weight of the composition.

### Claim 12 (depends on 10)

The method of claim 10, the composition comprising the 3-O-caffeoylquinic acid in an amount of from about 0.00001% to about 5% by weight of the composition.

### Claim 13 (depends on 1)

The method of claim 1, the composition comprising the total extract of Parrotia persica in an amount of from 10 μg/ml to 100 μg/ml.

### Claim 14 (depends on 1)

The method of claim 1, the wound comprising Adult Normal Human Epidermal Keratinocytes or Normal Human Dermal Fibroblasts.

### Claim 15 (depends on 1)

The method of claim 1, wherein the wound is a chronic wound.

### Claim 16 (depends on 1)

The method of claim 1, wherein the wound is a bedsore.

### Claim 17 (depends on 1)

The method of claim 1, wherein the wound is a wound to an internal tissue.